NCT04213677View on ClinicalTrials.gov

Dapagliflozin Efficacy and Action in PCOS

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

October 1, 2022

Study Completion Date

November 1, 2022

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Dapagliflozin

Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education.

DRUG

Placebo

Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.

Trial Locations (1)

510515

Nanfang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT04213677 - Dapagliflozin Efficacy and Action in PCOS | Biotech Hunter | Biotech Hunter